| Summary: | Glycopyrrolate has a Health Canada indication to reduce chronic, severe drooling in patients three to 18 years old with neurologic conditions associated with problem drooling (e.g., cerebral palsy). Glycopyrrolate is a synthetic quaternary ammonium anticholinergic drug that does not easily cross the blood-brain barrier. Glycopyrrolate inhibits the action of acetylcholine on salivary glands, thereby reducing the extent of salivation. It is available as an oral solution (1 mg/5 mL), with each mL containing 0.2 mg of glycopyrrolate. The Health Canada-recommended dosage is to initiate glycopyrrolate oral solution at 0.02 mg per kg of body weight three times DRUG REIMBURSEMENT RECOMMENDATION Glycopyrrolate Oral Solution (Cuvposa) - CDEC Meeting - November 20, 2019;CDEC Reconsideration Meeting - June 17, 2020; Notice of Final Recommendation - June 24, 20204daily and titrate in increments of 0.02 mg/kg every five to seven days based on therapeutic response and adverse reactions. The maximum recommended dosage is 0.1 mg/kg three times daily, not to exceed 1.5 mg to 3 mg per dose based on weight
|
|---|